Friday, April 18, 2014 5:19:58 PM
They thought about filing for orphan status for Dengue with both the FDA and European EMA and did.... and they were approved and so designated on both fronts.
They thought about up-listing to one of the major exchanges, and did.
They thought about scaling up their existing facility so they could save time completing the tox study vs. waiting for the new manufacturing facility to come on line and have now successfully completed that scale-up.
They thought about making preparations for clinical trials in Australia to save time and money. They have already retained local consultants to coordinate the regulatory review and approval to conduct the first human trials in Australia for Flucide.
They thought about bringing forth the legal filings necessary to expose the author of a libelous hit piece that is cowering behind the veil of anonymity and have done so with a ruling by the courts due to be made at the end of the month.
They thought about completing preliminary range finding tox studies to aid in conducting a much more efficient GLP tox study. They did so and with absolutely fabulous results showing no toxicity at Max Feasible Dose, a dose exceeding 100X the expected therapeutic dose.
They thought about contracting with Public Health England, LRRI, and ViroClinics to do IND enabling efficacy studies and have signed NDA's with all of the above with contracts in the final stages.
Virtually all of these things have been accomplished in the
last year.
Perhaps the "LIAR AWARD" rightfully belongs to somebody else?
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM